ClinicalTrials.gg
CompletedNCT06602024Updated Sep 16, 2026Results posted

A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age

A Phase 3 interventional study of mRNA-1010 and Fluarix® in Seasonal Influenza, sponsored by ModernaTX, Inc.. Completed at 301 sites in 11 countries. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
40,805
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human — 2 open to participants now, 2 under way, none of them phase 3. mRNA-1010 influenza vaccine · Influenza, Human.

Enrollment
Largest of 12
40,805 · median 471
Started
2024
the only one that year
Phase 3
4 of 12
none open now
Registered
10th of 12
by date
Lead sponsor
12 of 12
ModernaTX, Inc.

Among the 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human, this one has the largest enrollment, is the only one that started in 2024, is one of 4 in phase 3, and was the 10th registered.

Influenza, Human

2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

2 of the 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About mRNA-1010 influenza vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human, or all of them as a file.
02

Study summary

The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1010, and to evaluate relative vaccine efficacy (rVE) of mRNA-1010 versus an active comparator against reverse transcription polymerase chain reaction (RT-PCR)-confirmed protocol-defined influenza-like illness (ILI) caused by any influenza A or B strains.

03

Conditions studied

  • Seasonal Influenza

Browse trials for

Keywords

  • Seasonal Influenza
  • Flu
  • mRNA-1010
  • Vaccine
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Capable of giving signed , which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol.
  • Participants who are assigned female at birth or can become pregnant are eligible to participate if:

    • The participant is a person of nonchildbearing potential (PONCBP) or
    • The participant is a person of (POCBP) who:
  • Is not breast/chest feeding.
  • Is using an acceptable method at least 28 days prior to Day 1 (Baseline) to at least 90 days after Day 1 (Baseline).
  • Has a negative highly sensitive pregnancy test (urine or serum as required by local regulation or institutional review board [IRB]/independent ethics committee [IEC]) at the Screening Visit and before study intervention (if the Day 1 [Baseline] Visit is not on the same day as the Screening Visit).

Exclusion criteria

Exclusion Criteria:

  • Acutely ill or febrile (temperature ≥38.0 degrees Celsius (℃) [100.4° Fahrenheit [F]]) within 72 hours prior to Day 1 (Baseline).
  • Close contact with someone with laboratory-confirmed influenza infection or with someone who has been treated with antiviral therapies for influenza (for example, Tamiflu®/oseltamivir) within 5 days prior to Day 1 (Baseline).
  • History of a diagnosis or condition that, in the judgment of the Investigator, is clinically unstable or may affect participant safety, assessment of study endpoints, assessment of immune response, or adherence to study procedures.
  • Reported history of congenital or acquired immunodeficiency, condition, asplenia, or recurrent severe infections disease.
  • Tested positive for influenza by local health authority-approved testing methods within 180 days prior to Day 1 (Baseline).
  • History of anaphylaxis or severe reaction requiring medical intervention after receipt of any of the following: mRNA vaccine or therapeutic; components of an mRNA vaccine or therapeutic; influenza vaccine; or components of an influenza vaccine, including egg protein.
  • within 2 years prior to Day 1 (Baseline) (adequately treated basal cell carcinoma and squamous cell carcinoma are allowed).
  • Received at ≥10 milligram (mg)/day of prednisone or equivalent for >14 days in total within 90 days prior to Day 1 (Baseline) or is anticipating the need for corticosteroids at any time during the study.
  • Received systemic immunosuppressive treatment, including long-acting biological therapies that affect immune responses (for example, infliximab), within 180 days prior to Day 1 (Baseline) or plans to do so during the study.
  • Treated with antiviral therapies for influenza (for example, Tamiflu) within 180 days prior to Day 1 (Baseline).
  • Received any vaccine authorized or approved by local health agency within 28 days prior to Day 1 (Baseline) or plans to do so within 14 days after Day 1 (Baseline).
  • Received a licensed seasonal influenza vaccine within 180 days prior to Day 1 (Baseline) or plans to do so (outside of this study) at any time during the study.
  • Received an seasonal influenza vaccine within 1 year prior to Day 1 (Baseline). Note: participants from mRNA-1010-P304 Season 1 are NOT eligible to re enroll into Season 2.
  • Participated in a clinical study with investigational treatment within 90 days prior to Day 1 (Baseline) based on the medical history interview or plans to do so while participating in this study.
  • Is working or has worked as study personnel or is an immediate family member or house member of study personnel, study staff, or Sponsor personnel.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
40,805 participants (actual)

Study arms

  • Experimental
    mRNA-1010

    Participants will receive a single injection of mRNA-1010 on Day 1.

    Biological: mRNA-1010

  • Active comparator
    Fluarix®, Fluarix Tetra, Influsplit® Tetra, Alpharix® Tetra

    Participants will receive a single injection of active comparator trivalent influenza vaccine (TIV) or quadrivalent influenza vaccine (QIV) (Fluarix®, Fluarix Tetra, Influsplit® Tetra, Alpharix® Tetra) on Day 1.

    Biological: Fluarix® · Biological: Influsplit® Tetra · Biological: Fluarix Tetra · Biological: Alpharix® Tetra

Interventions

  • BiologicalmRNA-1010

    Intramuscular (IM) injection

  • BiologicalFluarix®

    IM injection

  • BiologicalInflusplit® Tetra

    IM injection

  • BiologicalFluarix Tetra

    IM injection

  • BiologicalAlpharix® Tetra

    IM injection

06

What researchers measure

Primary outcomes

  1. Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)

    Solicited ARs were recorded daily using electronic diaries (eDiaries). Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered adverse events (AEs). Investigator reviewed whether the solicited AR was also to be recorded as an AE. A summary of all Serious Adverse Events (SAEs) and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: Day 1 up to Day 7

  2. Number of Participants With Unsolicited Adverse Events (AEs)

    An unsolicited AE was defined as any AE reported by the participant that was not specified as a solicited AR in the protocol. An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A summary of all SAEs and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: Day 1 up to Day 28

  3. Number of Participants With Medically Attended AEs (MAAEs), AEs Leading to Study Discontinuation, SAEs, or Adverse Events of Special Interests (AESIs)

    MAAEs were AEs that led to an unscheduled visit to a healthcare provider. SAEs were AEs that resulted in death, were life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, a congenital anomaly or birth defect, or was a medically important event. AESIs were AEs (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program for which ongoing monitoring and immediate notification by the investigator to the Sponsor was required. A summary of all SAEs and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: Day 1 up to Day 181

  4. Number of Participants With First Episode of Reverse Tanscription Polymerase Chain Reaction (RT-PCR) Confirmed Protocol Defined Influenza-like Illness (ILI) Caused by Any Influenza A or B Strains

    Protocol-defined ILI: At least 1 systemic symptom (temperature \>37.2 degrees celsius \[°C\] \[\>99.0 degrees Fahrenheit {°F}\], chills, feverish, tiredness, headaches, or myalgia) and at least 1 respiratory symptom (sore throat, cough, sputum production, wheezing, or difficulty breathing).

    Time frame: Day 14 up to end of influenza season (up to 7.5 months)

Secondary outcomes

  1. Number of Participants With First Episode of RT-PCR Confirmed Modified United States (US) Centers for Disease Control and Prevention (CDC)-Defined ILI Caused by Any Influenza A or B Strains

    Modified CDC-defined ILI: Body temperature ≥37.2°C (≥99.0°F) accompanied by cough and/or sore throat.

    Time frame: Day 14 up to end of influenza season (up to 7.5 months)

  2. Number of Participants With First Episode of RT-PCR-confirmed Protocol-defined ILI or Modified CDC-defined ILI Caused by Any Influenza A or B Strains With Antigenic Match to the Vaccine Strains

    Protocol-defined ILI: At least 1 systemic symptom (temperature \>37.2°C \[\>99.0°F\], chills, feverish, tiredness, headaches, or myalgia) and at least 1 respiratory symptom (sore throat, cough, sputum production, wheezing, or difficulty breathing). Modified CDC-defined ILI: Body temperature \>37.2°C (\>99.0°F) accompanied by cough and/or sore throat. The confirmed RT-PCR test of influenza A or B strains with antigentic match to the vaccine strains.

    Time frame: Day 14 up to end of influenza season (up to 7.5 months)

  3. Geometric Mean Titer (GMT) of Hemagglutination Inhibition (HAI)

    Seasonal influenza A strains included H1N1 and H3N2 and seasonal influenza B strain included Victoria. Antibody values reported as below lower limit of quantification (LLOQ) were replaced by 0.5 \* LLOQ. Values greater than upper limit of quantification (ULOQ) were converted to ULOQ. LLOQ = 10, ULOQ = 3620 for H1N1. LLOQ = 10, ULOQ = 2560 for H3N2. LLOQ = 10, ULOQ = 1356. 95% confidence interval (CI) was calculated based on the t-distribution of log-transformed values for geometric mean (GM) titer, then back transformed to original scale for presentation.

    Time frame: Day 29

  4. Number of Participants Reaching Seroconversion as Measured by HAI

    Seroconversion was defined as either a Baseline HAI titer \<1:10 and a post-baseline titer ≥1:40 or a Baseline HAI titer ≥1:10 and a minimum 4-fold rise in post-baseline HAI antibody titer. Seasonal influenza A strains included H1N1 and H3N2 and seasonal influenza B strain included Victoria.

    Time frame: Day 29

  5. Number of Participants With an HAI Titer ≥1:40

    Seasonal influenza A strains included H1N1 and H3N2 and seasonal influenza B strain included Victoria.

    Time frame: Day 29

  6. Geometric Mean Fold Rise (GMFR) of HAI Titers

    Seasonal influenza A strains included H1N1 and H3N2 and seasonal influenza B strain included Victoria. 95% CI was calculated based on the t-distribution of the difference in the log-transformed values for GM fold rise, then back transformed to the original scale for presentation.

    Time frame: Baseline, Day 29

07

Results

Posted Sep 16, 2026

Participant flow

Participant flow — Overall Study
MilestonemRNA-1010Licensed Inactivated Seasonal Influenza Vaccine
Started2040220403
Received injection2034920354
Safety set2035020353
Per-protocol (pp) set2017920124
Solicited safety set30152997
Pp immunogenicity subset (ppis)11671175
Completed1956819622
Not completed834781
Withdrew: Adverse event32
Withdrew: Death4034
Withdrew: Lost to follow-up435420
Withdrew: Physician decision4225
Withdrew: Protocol violation21
Withdrew: Withdrawal by subject261255
Withdrew: Randomized by mistake1716
Withdrew: Other than specified3428

Outcome measures

PrimaryNumber of Participants With Solicited Local and Systemic Adverse Reactions (ARs)

Solicited ARs were recorded daily using electronic diaries (eDiaries). Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered adverse events (AEs). Investigator reviewed whether the solicited AR was also to be recorded as an AE. A summary of all Serious Adverse Events (SAEs) and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Time frame:
Day 1 up to Day 7
Reported as:
Count of participants · Participants
Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)
ParticipantsmRNA-1010Licensed Inactivated Seasonal Influenza Vaccine
Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)22831400
PrimaryNumber of Participants With Unsolicited Adverse Events (AEs)

An unsolicited AE was defined as any AE reported by the participant that was not specified as a solicited AR in the protocol. An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A summary of all SAEs and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Time frame:
Day 1 up to Day 28
Reported as:
Count of participants · Participants
Number of Participants With Unsolicited Adverse Events (AEs)
ParticipantsmRNA-1010Licensed Inactivated Seasonal Influenza Vaccine
Number of Participants With Unsolicited Adverse Events (AEs)12041167
PrimaryNumber of Participants With Medically Attended AEs (MAAEs), AEs Leading to Study Discontinuation, SAEs, or Adverse Events of Special Interests (AESIs)

MAAEs were AEs that led to an unscheduled visit to a healthcare provider. SAEs were AEs that resulted in death, were life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, a congenital anomaly or birth defect, or was a medically important event. AESIs were AEs (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program for which ongoing monitoring and immediate notification by the investigator to the Sponsor was required. A summary of all SAEs and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Time frame:
Day 1 up to Day 181
Reported as:
Count of participants · Participants
Number of Participants With Medically Attended AEs (MAAEs), AEs Leading to Study Discontinuation, SAEs, or Adverse Events of Special Interests (AESIs)
ParticipantsmRNA-1010Licensed Inactivated Seasonal Influenza Vaccine
MAAEs25092439
AEs Leading to Study Discontinuation31
SAEs455392
AESIs1715
PrimaryNumber of Participants With First Episode of Reverse Tanscription Polymerase Chain Reaction (RT-PCR) Confirmed Protocol Defined Influenza-like Illness (ILI) Caused by Any Influenza A or B Strains

Protocol-defined ILI: At least 1 systemic symptom (temperature \>37.2 degrees celsius \[°C\] \[\>99.0 degrees Fahrenheit {°F}\], chills, feverish, tiredness, headaches, or myalgia) and at least 1 respiratory symptom (sore throat, cough, sputum production, wheezing, or difficulty breathing).

Time frame:
Day 14 up to end of influenza season (up to 7.5 months)
Reported as:
Count of participants · Participants
Number of Participants With First Episode of Reverse Tanscription Polymerase Chain Reaction (RT-PCR) Confirmed Protocol Defined Influenza-like Illness (ILI) Caused by Any Influenza A or B Strains
ParticipantsmRNA-1010Licensed Inactivated Seasonal Influenza Vaccine
Number of Participants With First Episode of Reverse Tanscription Polymerase Chain Reaction (RT-PCR) Confirmed Protocol Defined Influenza-like Illness (ILI) Caused by Any Influenza A or B Strains411577
Statistical analysis
  • mRNA-1010 vs Licensed Inactivated Seasonal Influenza Vaccine · Stratified Cox proportional hazard model · p = < 0.0001 · Rve: 26.6 · 95% CI 16.7 to 35.4
  • mRNA-1010 vs Licensed Inactivated Seasonal Influenza Vaccine · Stratified Cox proportional hazard model · p = < 0.0001 · Rve: 26.6 · 95% CI 16.7 to 35.4
  • mRNA-1010 vs Licensed Inactivated Seasonal Influenza Vaccine · Stratified Cox proportional hazard model · p = = 0.0005 · Rve: 26.6 · 95% CI 16.7 to 35.4
SecondaryNumber of Participants With First Episode of RT-PCR Confirmed Modified United States (US) Centers for Disease Control and Prevention (CDC)-Defined ILI Caused by Any Influenza A or B Strains

Modified CDC-defined ILI: Body temperature ≥37.2°C (≥99.0°F) accompanied by cough and/or sore throat.

Time frame:
Day 14 up to end of influenza season (up to 7.5 months)
Reported as:
Count of participants · Participants
Number of Participants With First Episode of RT-PCR Confirmed Modified United States (US) Centers for Disease Control and Prevention (CDC)-Defined ILI Caused by Any Influenza A or B Strains
ParticipantsmRNA-1010Licensed Inactivated Seasonal Influenza Vaccine
Number of Participants With First Episode of RT-PCR Confirmed Modified United States (US) Centers for Disease Control and Prevention (CDC)-Defined ILI Caused by Any Influenza A or B Strains223290
SecondaryNumber of Participants With First Episode of RT-PCR-confirmed Protocol-defined ILI or Modified CDC-defined ILI Caused by Any Influenza A or B Strains With Antigenic Match to the Vaccine Strains

Protocol-defined ILI: At least 1 systemic symptom (temperature \>37.2°C \[\>99.0°F\], chills, feverish, tiredness, headaches, or myalgia) and at least 1 respiratory symptom (sore throat, cough, sputum production, wheezing, or difficulty breathing). Modified CDC-defined ILI: Body temperature \>37.2°C (\>99.0°F) accompanied by cough and/or sore throat. The confirmed RT-PCR test of influenza A or B strains with antigentic match to the vaccine strains.

Time frame:
Day 14 up to end of influenza season (up to 7.5 months)
Reported as:
Count of participants · Participants
Number of Participants With First Episode of RT-PCR-confirmed Protocol-defined ILI or Modified CDC-defined ILI Caused by Any Influenza A or B Strains With Antigenic Match to the Vaccine Strains
ParticipantsmRNA-1010Licensed Inactivated Seasonal Influenza Vaccine
Protocol-defined ILI261364
Modified CDC-defined ILI143198
SecondaryGeometric Mean Titer (GMT) of Hemagglutination Inhibition (HAI)

Seasonal influenza A strains included H1N1 and H3N2 and seasonal influenza B strain included Victoria. Antibody values reported as below lower limit of quantification (LLOQ) were replaced by 0.5 \* LLOQ. Values greater than upper limit of quantification (ULOQ) were converted to ULOQ. LLOQ = 10, ULOQ = 3620 for H1N1. LLOQ = 10, ULOQ = 2560 for H3N2. LLOQ = 10, ULOQ = 1356. 95% confidence interval (CI) was calculated based on the t-distribution of log-transformed values for geometric mean (GM) titer, then back transformed to original scale for presentation.

Time frame:
Day 29
Reported as:
Geometric mean · titer
Geometric Mean Titer (GMT) of Hemagglutination Inhibition (HAI)
titermRNA-1010Licensed Inactivated Seasonal Influenza Vaccine
Influenza A H1N1 Antibody146.15 ± 136.4380.08 ± 74.98
Influenza A H3N2 Antibody149.48 ± 140.1992.60 ± 86.85
Influenza B/ Victoria250.92 ± 237.83149.64 ± 142.08
SecondaryNumber of Participants Reaching Seroconversion as Measured by HAI

Seroconversion was defined as either a Baseline HAI titer \<1:10 and a post-baseline titer ≥1:40 or a Baseline HAI titer ≥1:10 and a minimum 4-fold rise in post-baseline HAI antibody titer. Seasonal influenza A strains included H1N1 and H3N2 and seasonal influenza B strain included Victoria.

Time frame:
Day 29
Reported as:
Count of participants · Participants
Number of Participants Reaching Seroconversion as Measured by HAI
ParticipantsmRNA-1010Licensed Inactivated Seasonal Influenza Vaccine
Influenza A H1N1 Antibody642318
Influenza A H3N2Antibody710480
Influenza B/ Victoria526232
SecondaryNumber of Participants With an HAI Titer ≥1:40

Seasonal influenza A strains included H1N1 and H3N2 and seasonal influenza B strain included Victoria.

Time frame:
Day 29
Reported as:
Count of participants · Participants
Number of Participants With an HAI Titer ≥1:40
ParticipantsmRNA-1010Licensed Inactivated Seasonal Influenza Vaccine
Influenza A H1N1 Antibody1079940
Influenza A H3N2 Antibody10901008
Influenza B/ Victoria11591151
SecondaryGeometric Mean Fold Rise (GMFR) of HAI Titers

Seasonal influenza A strains included H1N1 and H3N2 and seasonal influenza B strain included Victoria. 95% CI was calculated based on the t-distribution of the difference in the log-transformed values for GM fold rise, then back transformed to the original scale for presentation.

Time frame:
Baseline, Day 29
Reported as:
Geometric mean · ratio
Geometric Mean Fold Rise (GMFR) of HAI Titers
ratiomRNA-1010Licensed Inactivated Seasonal Influenza Vaccine
Influenza A H1N1 Antibody4.07 ± 3.842.24 ± 2.11
Influenza A H3N2 Antibody4.70 ± 4.442.98 ± 2.81
Influenza B/ Victoria3.14 ± 2.991.88 ± 1.80

Adverse events

Collected over All-cause mortality, SAEs, AESIs, MAAEs, and AEs led to study discontinuation: Day 1 up to Day 181. Non-serious AEs: up to 28 days after study injection, unless they met criteria for AESIs, MAAEs, or AEs led to study discontinuation.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
mRNA-101040/20,402 (0.2%)455/20,350 (2.2%)0/20,350 (0%)
Licensed Inactivated Seasonal Influenza Vaccine34/20,403 (0.2%)392/20,353 (1.9%)0/20,353 (0%)
Most frequent serious events
Showing 10 of 463
Most frequent serious events
EventmRNA-1010Licensed Inactivated Seasonal Influenza Vaccine
Cerebrovascular accidentNervous system disorders15/2035013/20353
Atrial fibrillationCardiac disorders14/203506/20353
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders14/203507/20353
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)6/88343/8720
Cardiac failure congestiveCardiac disorders13/203506/20353
DeathGeneral disorders12/203504/20353
SepsisInfections and infestations7/2035011/20353
Acute respiratory failureRespiratory, thoracic and mediastinal disorders10/203502/20353
Acute myocardial infarctionCardiac disorders5/2035010/20353
Myocardial infarctionCardiac disorders9/203503/20353

Baseline characteristics

Randomization set included all participants who were randomized, regardless of the participants' treatment status in the study. Participants were analyzed according to the treatment group to which they were randomized.

Age, Continuous
Age, Continuous(years)mRNA-1010Licensed Inactivated Seasonal Influenza VaccineTotal
Mean64.2 ± 8.2864.2 ± 8.3664.2 ± 8.32
Sex: Female, Male
Sex: Female, Male(Participants)mRNA-1010Licensed Inactivated Seasonal Influenza VaccineTotal
Female115451166223207
Male8857874117598
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)mRNA-1010Licensed Inactivated Seasonal Influenza VaccineTotal
Hispanic or Latino215120724223
Not Hispanic or Latino179561802935985
Unknown or Not Reported295302597
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)mRNA-1010Licensed Inactivated Seasonal Influenza VaccineTotal
Race — White168511685333704
Race — Black or African American269827065404
Race — Asian499483982
Race — American Indian or Alaska Native7286158
Race — Native Hawaiian or Other Pacific Islander201939
Race — Multiple110104214
Race — Other5155106
Race — Unknown151631
Race — Not Reported8681167
08

Study locations

301 sites
  • Pinnacle Research Group, Llc
    Anniston, Alabama 36207, United States
  • North Alabama Research Center, LLC
    Athens, Alabama 35611, United States
  • Flourish Research
    Birmingham, Alabama 35209, United States
  • EmVenio Research Brimingham, AL
    Birmingham, Alabama 35210, United States
  • Cullman Clinical Trials
    Cullman, Alabama 35055, United States
  • Optimal Research
    Huntsville, Alabama 35802, United States
  • Velocity Clinical Research
    Mobile, Alabama 36608, United States
  • Lenzmeier Family Medicine
    Glendale, Arizona 85308, United States
  • DM Clinical Research
    Phoenix, Arizona 85012, United States
  • Helios Clinical Research
    Phoenix, Arizona 85028, United States
  • Fiel Family and Sports Medicine
    Tempe, Arizona 85283, United States
  • Arizona Liver Health
    Tucson, Arizona 85711, United States
  • Baptist Health Center for Clinical Research
    Little Rock, Arkansas 72205, United States
  • Woodland Research
    Rogers, Arkansas 72758, United States
  • Benchmark Research - Colton
    Colton, California 92324, United States
  • Flourish Research
    Covina, California 91723, United States
  • Velocity Clinical Research - Huntington Park
    Huntington Park, California 90255, United States
  • Velocity Clinical Research, San Diego
    La Mesa, California 91942, United States
  • Long Beach Research Institute LLC
    Long Beach, California 90805, United States
  • Velocity Clinical Research - Westlake
    Los Angeles, California 90057, United States
  • M3 Wake Research/PRI, LLC
    Newport Beach, California 92660, United States
  • Carbon Health North Hollywood
    North Hollywood, California 91606, United States
  • Valley Clinical Trials, Inc.
    Northridge, California 91325, United States
  • Paradigm Research
    Redding, California 96001, United States
  • Artemis Institute for Clinical Research
    Riverside, California 92503, United States
  • Peninsula Research Associates (PRA)
    Rolling Hills Estates, California 90274, United States
  • Velocity Clinical Research - Banning
    San Bernardino, California 92408, United States
  • Artemis Institute for Clinical Research - Research Site
    San Diego, California 92103, United States
  • WHCR- M3 Wake Research
    San Diego, California 92111, United States
  • Wr-McCr, Llc
    San Diego, California 92120, United States
  • Velocity Clinical Research
    Santa Ana, California 92704, United States
  • Diablo Clinical Research
    Walnut Creek, California 94598, United States
  • Tekton Research - Fort Collins
    Fort Collins, Colorado 80525, United States
  • Tekton Research, Inc - Longmont Center
    Longmont, Colorado 80501, United States
  • Stamford Therapeutics Consortium
    Stamford, Connecticut 06905, United States
  • Chase Medical Research, LLC
    Waterbury, Connecticut 06708, United States
  • JEM Research Institue
    Atlantis, Florida 33462, United States
  • Nature Coast Clinical Research, LLC - Crystal River
    Crystal River, Florida 34429, United States
  • Homestead Associates in Research,Inc
    Hialeah, Florida 33016, United States
  • CenExel RCA
    Hollywood, Florida 33024, United States
  • Nature Coast Clinical Research, LLC - Inverness
    Inverness, Florida 34452, United States
  • Westside Center for Clinical Research
    Jacksonville, Florida 32205-4785, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • Health Awareness INC
    Jupiter, Florida 33458, United States
  • M3 Wake Research/MSRA,LLC
    Lake City, Florida 32055, United States
  • Accel Clinical Research
    Lake Mary, Florida 32746, United States
  • Clinical Site Partners - Leesburg
    Leesburg, Florida 34748, United States
  • ARS - Meridien Research
    Maitland, Florida 32751, United States
  • K2 medical research
    Maitland, Florida 32751, United States
  • South Florida Research Center, Inc.
    Miami, Florida 33135, United States
  • Miami Clinical Research
    Miami, Florida 33155, United States
  • Suncoast Research Associates, LLC
    Miami, Florida 33173, United States
  • Floridian Clinical Research
    Miami Lakes, Florida 33016, United States
  • Headlands Research
    Orlando, Florida 32819, United States
  • Suncoast Research Associates
    Pembroke Pines, Florida 33024, United States
  • Health Awareness INC
    Port Saint Lucie, Florida 34952, United States
  • IMA Clinical Research Warren
    St. Petersburg, Florida 33704, United States
  • Forward Clinical Trials - Dermatology
    Tampa, Florida 33613, United States
  • Clinical Site Partners, LLC
    Winter Park, Florida 32789, United States
  • JAVARA
    Albany, Georgia 31707, United States
  • IACT Health
    Columbus, Georgia 31904, United States
  • CenExel iResearch , LLC
    Decatur, Georgia 30030, United States
  • CenExel iResearch Savannah
    Savannah, Georgia 31405, United States
  • Velocity Clinical Research-Savannah
    Savannah, Georgia 31406-2675, United States
  • Javara - Privia Medical Group Georgia, LLC
    Savannah, Georgia 31406, United States
  • Clinical Research Atlanta/Headlands
    Stockbridge, Georgia 30281, United States
  • East-West Medical Research Institute
    Honolulu, Hawaii 96814-4526, United States
  • Bingham Memorial Hospital
    Blackfoot, Idaho 83221, United States
  • Velocity Clinical Research - Boise
    Meridian, Idaho 83642, United States
  • EmVenio Research
    Chicago, Illinois 60608, United States
  • Great Lakes Clinical Trials
    Chicago, Illinois 60640, United States
  • DM Clinical Research- River Forest
    Melrose Park, Illinois 60160, United States
  • Velocity Clinical Research - Valparaiso
    Valparaiso, Indiana 46383, United States
  • Velocity Clinical Research-Sioux City
    Sioux City, Iowa 51106, United States
  • Alliance for Multispecialty Research
    Augusta, Kansas 67010, United States
  • Johnson County Clin-Trials (JCCT)
    Lenexa, Kansas 66219-1376, United States
  • DelRicht Research - Overland Park
    Overland Park, Kansas 66209, United States
  • AMR
    Wichita, Kansas 67207, United States
  • Velocity Clinical Research - Baton Rouge
    Baton Rouge, Louisiana 70809, United States
  • Velocity Clinical Research - Lafayette
    Lafayette, Louisiana 70508, United States
  • IMA Clinical Research Monroe
    Monroe, Louisiana 71201, United States
  • DelRicht Research
    New Orleans, Louisiana 70115, United States
  • Velocity Clinical Research
    New Orleans, Louisiana 70119, United States
  • DelRicht Research @ Neighborhood Health
    Prairieville, Louisiana 70769-4212, United States
  • Privia Medical Group
    Annapolis, Maryland 21401, United States
  • Cenexel CBH (CBH Health)
    Gaithersburg, Maryland 20877, United States
  • Matthew Mintz Clinic
    Rockville, Maryland 20852, United States
  • Velocity Clinical Research - Covington
    Rockville, Maryland 20854, United States
  • DM Clinical Research - Brookline
    Brookline, Massachusetts 02446, United States
  • Headlands Research - Detroit
    Southfield, Michigan 48034, United States
  • Great Lakes Research Institute
    Southfield, Michigan 48075-5400, United States
  • DM Clinical Research
    Southfield, Michigan 48076, United States
  • DELRICHT RESEARCH at GULFPORT MEMORIAL
    Gulfport, Mississippi 39503, United States
  • Clinical Research Professionals
    Chesterfield, Missouri 63005, United States
  • Clinvest
    Springfield, Missouri 65807, United States
  • Delricht Research
    Springfield, Missouri 65807, United States
  • Sundance Clinical Research, LLC
    St Louis, Missouri 63141, United States
  • Delricht
    Town and Country, Missouri 63017, United States
  • Boeson Research MSO
    Missoula, Montana 59804, United States
  • Elias Research Associates
    Missoula, Montana 59808, United States

Showing the first 100 of 301 sites across 11 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Leroux-Roels I, Huang G, Ferguson M, Kohli A, Clark R, Bickel M, Soens M, Du E, Pucci A, Hicks B, Eschen C, Das R, Wilson E; Fluent Trial Investigators. Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults. N Engl J Med. 2026 May 7;394(18):1803-1813. doi: 10.1056/NEJMoa2516491. PubMed 42090792 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Aug 2025, 11 months.

Results were first posted in Sep 2026, 1 year after primary completion.

Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's 11 months is above that.

Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2024
First posted
Sep 19, 2024
StartActual
Sep 16, 2024
Primary completionActual
Aug 21, 2025
CompletionActual
Aug 21, 2025
Results first posted
Sep 16, 2026
Last update
Sep 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06602024
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Sep 16, 2024
Primary completion
Aug 21, 2025
Completion
Aug 21, 2025
Results posted
Sep 16, 2026
Last update
Sep 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: mRNA-1010 influenza vaccine

Start the discussion